Drug intelligence / Profile preview

JW0110

Development stage: Unknown
Lead developer: JW Pharmaceutical
Modality: Small Molecules

Overview

**JW0110** is a JW Pharmaceutical development code for an undisclosed small-molecule fixed-dose combination being developed for diabetes and hyperlipidemia. JW Pharmaceutical lists the candidate in its cardiovascular and metabolic disease pipeline at Phase 1 and categorizes it as a modified new drug fixed-dose combination. The individual active ingredients, molecular targets, pharmacologic mechanism, formulation details, and route of administration have not been publicly disclosed. ([jw-pharma.co.kr](https://www.jw-pharma.co.kr/pharma/en/rnd/research_pipeline.jsp))

Brand names: Livalo FenoLivalo Feno Capsule
Other names: pitavastatin + fenofibrate

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on JW0110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0110.

Explore the full profile